Arcus cancels work on Gilead-partnered cancer combo after trial setback

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target.

Jonathan Gardner Member since November 15, 2023

Loading + Follow Following